Kiniksa Pharmaceuticals International, plc

and thank you for standing by. Welcome to the Connexin Pharmaceuticals Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in the listen-only mode. After the speaker presentation, there will be a question and answer session. At that time, if you have a question, you will need to press star 1 on your telephone. If anyone should require assistance during the conference, please press star 0. I will now like to hand the conference over to your host, Rachel Frank. Please go ahead.

Thank you, operator. Good morning, and thank you for joining Connexa's call to discuss our second quarter 2021 financial results in our recent corporate and pipeline activity. A press release highlighting these results can be found on our website under the Investors and Media section. As for the agenda, our CEO, Sanj K. Patel, will start with an introduction. Ross Mote, our head of commercial, will detail our commercial launch. John Paolini, Conexa's chief medical officer, will follow with a brief pipeline update, including a review of additional data from our Maverillimumab Phase 2 clinical trial in COVID-19-related ARDS. Mark Ragoza, our chief financial officer, will review our second quarter 2021 financial results. And finally, Sanj will return for closing remarks. and to kick off the Q&A session for which Evan Tesari, our Chief Business Officer, will also be on the line. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption, Risk Factors, contained in our SEC file. These statements speak only as of the date of this presentation and we undertake no obligation to update such statements except as required by law. With that, I will turn it over to Sanj.

Thanks, Rachel, and good morning, everyone. I'm incredibly excited to have the opportunity to discuss our second quarter 2021 results today, which include the first quarter of ARCLIS sales in recurrent pericarditis. We are very encouraged by our initial launch progress, and that is a direct result of focused execution by the Conixta team. I'm excited to report that net revenue for Arclist for the second quarter of 2021 was $7.7 million. While we are still in the early stages of the launch, the team continues to execute extremely well. The pre-launch work that they've done to identify the patient population provided a clear call to action for physicians to prescribe. And the team continues to identify patients and expand upon the prescribing base. All these efforts have facilitated the encouraging uptake that we've seen to date and positions us for continued growth in the coming quarters and years. Ross will cover our commercial performance in a bit more detail, and as you'll hear, we are very pleased with the breadth of physician and patient adoption, as well as the viable reimbursement condition ahead of payers establishing coverage policy. Aside from Arclist, we're also focused on building maximum value across our entire portfolio. Over the last few months, we've continued to execute across our pipeline of clinical stage product candidates. In particular, in the past quarter, we were pleased to announce positive results for Mavilimumab in the Phase II trial in severe COVID-19-related ARDS, as well as positive final data from the Phase I trial of KPL-404, which is our CD40 program. John Paolini will provide a more detailed update on the recent pipeline progress, but in essence, we believe we are well-positioned for longer-term growth with Arclist. And our pipeline assets, Mavalimumab, Vixorumab, and KPL-404 will also aid our growth. I'll now turn it over to Ross to discuss our commercial performance in more detail. Over to you, Ross.